Early Stop(Ruling) of the Antibiotic Treatment During Pneumopathies d' Inhalation
Key facts
- Who runs it
- University Hospital, Lille
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 266 people enrolled
- Started
- 20 Sept 2019
- Ended
- 22 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- PCR-based microbiological diagnosis strategy
- Standard microbiological diagnosis strategy
- Record updated
- 23 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- presence of risk factors for aspiration :
- known or likely swallowing dysfunction,
- altered consciousness,
- cardiac arrest,
- difficult intubation
- witnessed aspiration
- symptoms and signs suggestive of lower respiratory tract pathology
- temperature ≥38.5°C or <36°C
- leukocyte count ≥10 000/µL or <1500/µL
- purulent sputum or tracheal aspirate
- new radiographic infiltrate on chest X-ray
- tracheal intubation and mechanical ventilation since less than 48 hours
Who cannot take part
- severe immunosuppression: leukocytes<1000/L or neutrophils<500/L, chemotherapy during the last 3 months, organ transplant with chronic immunosuppressors use, HIV (CD4<50), and chronic corticosteroid use (>0.5 mg/kg day for at least one month during the last three months)
- pregnant women
- refuse to participate to the study
- no informed consent
- documented bacteremia
- septic shock
- moribund patients (SAPS II >90)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The two most common consequences resulting from aspiration are chemical pneumonitis and bacterial aspiration pneumonia. Both entities present with comparable clinical signs and symptoms. In the absence of a reliable clinical or biological marker to differentiate between these two conditions, most patients with suspected aspiration are treated empirically with antibiotics. De-escalation of initial antibiotic treatment is encouraged based on the results of microbiological results, usually performed before starting antimicrobial treatment. However, in most hospitals, 48-72h are required to obtain the results of microbiological cultures, and to de-escalate empirical large spectrum antibiotic treatment.
Read full original descriptionShow less
The use of the Unyvero®, a multiplex PCR-based testing system, for detection of respiratory bacterial pathogens would allow decreasing the percentage of patients with aspiration syndrome who will receive unappropriated antibiotic treatment at Day 3.
The 2 groups in the trial
- multiplex PCR strategyTreatment being tested
FilmArray® Pneumonia Panel plus
Treatment: PCR-based microbiological diagnosis strategy
- standard strategyExisting treatment, for comparison
Treatment: Standard microbiological diagnosis strategy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of a Strategy Based on the Unyvero® Testing System on Appropriate Antimicrobial Treatment in Patients With Suspected Aspiration Pneumonia Requiring Mechanical Ventilation : a Randomized Controlled Unblinded Trial
- Record updated
- 23 December 2025